Tuberculosis Diagnostics Market Size And Forecast By Test Types (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance) And Trend Analysis From 2013 to 2024

Published: Sep, 2015 | Pages: 92 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The global tuberculosis diagnostics market is expected to reach USD 3.1 billion by 2024, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Further key findings from the study suggest:

Based on tests type, the tuberculosis diagnostics market is segmented into radiographic methods, diagnostic laboratory methods, nucleic acid testing, phage assay, detection of latent infection, cytokine detection assay, and detection of drug resistance.

Diagnostic laboratory tests dominated the test type segment with 38.0% market share in 2015 as they are cost efficient and easy-to-perform. Diagnostic laboratory tests include smear microscopy and culture-based tests. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies thus contributing to the growth of the diagnostic laboratory tests segment.

However, compromised accuracy and the longer processing time are the limiting factor for the diagnostics. Hence, healthcare agencies are striving to implement advanced techniques in the developing regions.

As a result, nucleic acid tests segment and the latent infection detection segment, which includes skin tests and IGRA, are likely to exhibit a profitable growth rate. These methods overcome the aforementioned limitations thus improving affordability, processing time and accuracy of the diagnostic method.

Drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimen and incorrect dosage forms lead to the development of drug resistance in TB patients undergoing treatment. Hence, the drug resistance detection segment is also anticipated to witness lucrative growth.

Asia Pacific owing to its huge population base and high burden of TB dominated the global TB diagnostics market in 2015. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for control of this communicable disease.

The players in the TB testing market include Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH, and QIAGEN.

New product launches, collaboration, mergers & acquisitions, and regional expansion are the key strategic initiatives undertaken by these industry players

For instance, in July 2016, bioMerieux launched a novel CE marked database and reagents kit VITEK MS for the identification of TB. This new product launch is anticipated to help the company increase its market share.

 Table of Contents


Chapter 1 Research Methodology
                       1.1 Research Methodology
                       1.2 Research Scope & Assumptions
                       1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Market Summary
Chapter 4 Market Variables, Trends & Scope
                       4.1 Market Segmentation & Scope
                       4.2 Market Driver Analysis
                       4.3 Market Restraint Analysis
                       4.4 Penetration & Growth Prospect Mapping
                       4.5 SWOT Analysis, By Factor
                          4.5.1 Political
                          4.5.2 Economic
                          4.5.3 Technology
Chapter 5 Market Categorization 1: Test Types Estimates & Trend Analysis 
                       5.1 Test Types Movement Analysis & Market Share, 2015 & 2024
                       5.2 Market Size & Forecasts and Trend Analyses, 2013 to 2024 for the following products:
                          5.2.1 Radiographic method
                          5.2.2 Diagnostic Laboratory methods
                                5.2.2.1 Smear microscopy
                                5.2.2.2 Culture-based test 
                          5.2.3 Nucleic acid testing
                          5.2.4 Phage assay
                          5.2.5 Detection of latent infection 
                          5.2.6 Cytokine detection assay 
                          5.2.7 Detection of drug resistance 
                          5.2.8 Other methods
Chapter 6 Market Categorization 2: Regional Estimates & Trend Analysis
                       6.1 Regional Movement Analysis & Market Share, 2015 & 2024
                       6.2 Market Size & Forecasts and Trend Analyses, 2013 to 2024 for the following regions:
                          6.2.1 North America
                                6.2.1.1 U.S.
                                6.2.1.2 Canada
                          6.2.2 Europe
                                6.2.2.1 UK
                                6.2.2.2 Russian Fedration
                          6.2.3 Asia Pacific
                                6.2.3.1 China
                                6.2.3.2 India
                          6.2.4 Latin America
                                6.2.4.1 Brazil
                                6.2.4.2 Mexico
                          6.2.5 MEA
                                6.2.5.1 South Africa
Chapter 7 Competitive Landscape
                       7.1 Strategy Framework
                       7.2 Company Profiles
                          7.2.1 Abbott Laboratories
                                7.2.1.1 Company Overview
                                7.2.1.2 Financial Performance
                                7.2.1.3 Product Benchmarking
                                7.2.1.4 Strategic Initiatives
                          7.2.2 Alere, Inc.
                                7.2.2.1 Company Overview
                                7.2.2.2 Financial Performance
                                7.2.2.3 Product Benchmarking
                                7.2.2.4 Strategic Initiatives
                          7.2.3 Becton, Dickinson and Company
                                7.2.3.1 Company Overview
                                7.2.3.2 Financial Performance
                                7.2.3.3 Product Benchmarking
                                7.2.3.4 Strategic Initiatives
                          7.2.4 F.Hoffmann-La Roche AG
                                7.2.4.1 Company Overview
                                7.2.4.2 Financial Performance
                                7.2.4.3 Product Benchmarking
                                7.2.4.4 Strategic Initiatives
                          7.2.5 Siemens 
                                7.2.5.1 Company Overview
                                7.2.5.2 Financial Performance
                                7.2.5.3 Product Benchmarking
                                7.2.5.4 Strategic Initiatives
                          7.2.6 bioMerieux SA
                                7.2.6.1 Company Overview
                                7.2.6.2 Financial Performance
                                7.2.6.3 Product Benchmarking
                                7.2.6.4 Strategic Initiatives
                          7.2.7 Cepheid
                                7.2.7.1 Company Overview
                                7.2.7.2 Financial Performance
                                7.2.7.3 Product Benchmarking
                                7.2.7.4 Strategic Initiatives
                          7.2.8 Hain Lifesciences GmBH
                                7.2.8.1 Company Overview
                                7.2.8.2 Financial Performance
                                7.2.8.3 Product Benchmarking
                                7.2.8.4 Strategic Initiatives
                          7.2.9 Hologic Corporation
                                7.2.9.1 Company Overview
                                7.2.9.2 Financial Performance
                                7.2.9.3 Product Benchmarking
                                7.2.9.4 Strategic Initiatives

List of Tables


TABLE 1 North America tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 2 North America diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 3 U.S. tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 4 U.S. diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 5 Canada tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 6 Canadadiagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 7 Europe tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 8 Europe diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 9 UK tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 10 UK diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 11 Russian Federation tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 12 Russian Federation diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 13 Asia Pacific tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 14 Asia Pacific diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 15 China tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 16 China diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 17 India tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 18 India diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 19 Latin America tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 20 Latin America diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 21 Brazil tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 22 Brazil diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 23 Mexico tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 24 Mexico diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 25 MEA tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 26 MEA diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)
TABLE 27 South Africa tuberculosis disgnostics market, by test type, 2013 - 2024 (USD Million)
TABLE 28 South Africa diagnostic laboratory methods market, by type, 2013 - 2024 (USD Million)